AUPH — Aurinia Pharmaceuticals Inc
Is AUPH overbought or oversold? Here is the current MarketMoodz read.
Aurinia Pharmaceuticals Inc (AUPH) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $15.40. The rating moved from Neutral to Oversold on November 12, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$15.40
- Last changeMoved from Neutral to Oversold on November 12, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Aurinia Pharmaceuticals Inc (AUPH) is a specialty biotech whose near‑term performance is driven primarily by commercial execution of its lead therapy in nephrology/transplant markets and the company’s ability to sustain operations without dilutive capital. Financial health depends on current cash runway, expense control, and revenue growth from prescription uptake and payer coverage. Competitive and reimbursement dynamics create meaningful downside if access or pricing weakens, while sector themes—ongoing large‑cap M&A into specialty franchises and sustained distributor/specialty pharmacy flows—support strategic interest that could provide upside through partnership or acquisition. Social sentiment and filings data are limited, increasing sensitivity to discrete news and earnings. Near term, expect consolidation-range trading with upside tied to clear revenue beat, improved payer access, or acquisition speculation; downside would be triggered by disappointing sales, safety/regulatory developments, or need for dilutive financing.
Key factors
- Commercial traction of core product (LUPKYNIS) as primary revenue driver and its uptake trends in specialty nephrology and transplant markets
- Cash runway and balance sheet adequacy vs. burn rate for near‑term operations and potential need for financing or partnership
- Regulatory and payer environment for immunomodulatory therapies, including reimbursement dynamics and formulary access
- Sector flows favoring defensive large‑cap pharma and consolidation, which increases strategic exit / M&A optionality for specialty franchises
- Distributor and specialty pharmacy channel trends that could support prescription fulfillment and specialty care adoption
- Concentration risk from reliance on a small portfolio; limited late‑stage pipeline breadth increases single‑asset sensitivity
Risks
- Single‑product dependency—weak commercial performance or safety/regulatory setbacks for the lead asset would materially pressure revenue and share price
- Reimbursement headwinds or restrictive payer coverage limiting patient access and pricing power
- Need for dilutive financing if cash runway is insufficient or if commercial investments require more capital than expected
- Competition from other immunosuppressants, novel therapies, or off‑label use that could cap market share
- Low liquidity and higher volatility typical of small‑cap biotechs, amplifying downside on negative news
- Uncertain social/sentiment signals and limited analyst coverage that can widen intraday moves around newsflow
See today's live rating, score and targets
Members see the live hourly rating for AUPH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.